Towards Precision Medicine in Inflammatory Bowel Diseases: Pharmacogenetic Predictors of Ustekinumab Effectiveness and Persistence
Ylenia Marino, Michelangelo Rottura, Claudia Ligresti, Antonio Battaglia, Clara De Francesco, Natasha Irrera, Vincenzo Arcoraci, Walter Fries, Anna Viola, Giovanni Pallio · 2026
Read Towards Precision Medicine in Inflammatory Bowel Diseases: Pharmacogenetic Predictors of Ustekinumab Effectiveness and Persistence by Ylenia Marino, Michelangelo Rottura, Claudia Ligresti, Antonio Battaglia, Clara De Francesco, Natasha Irrera, Vincenzo Arcoraci, Walter Fries, Anna Viola, Giovanni Pallio (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13610517.txt.
Description
Ylenia Marino and co-authors ask whether genes predict who thrives on a bowel disease drug in a study from 2026. Crohn's disease and ulcerative colitis answer biologic drugs unevenly. Ustekinumab, which blocks the IL-12 and IL-23 pathway, helps many but not all. Nobody knows in advance who will stay the course.
Ninety-eight patients on the drug in routine care were followed. Steroid-free remission at twelve months was the main target. Persistence on therapy mattered beside it. Genetic markers tied to drug handling were tested against both outcomes. A predictive gene panel could spare non-responders months of false hope. Precision prescribing in bowel disease starts with studies like this.
Catalog record
| CREATOR | Ylenia Marino, Michelangelo Rottura, Claudia Ligresti, Antonio Battaglia, Clara De Francesco, Natasha Irrera, Vincenzo Arcoraci, Walter Fries, Anna Viola, Giovanni Pallio |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |